Regulatory Affairs · Medical Writing · Competitive Intelligence
LucidBio Intelligence places experts who have personally led comparable programs through FDA directly into your team — owning the work end to end, from IND through BLA.
Our Expertise
Unlike traditional CROs that assign generalist teams, LucidBio places proven program leaders with direct prior experience in your indication — senior experts embedded from day one, accountable to your milestones.
Regulatory strategy and submission management led by experts who have personally navigated FDA for programs in your indication and modality.
Authored by senior medical writers embedded in your team — not managed remotely by a generalist writing pool — to the standard FDA expects at your next milestone.
AI-powered intelligence calibrated to life sciences regulatory and clinical nuances — delivering the competitive picture your board and investors need.
Featured Report
Regulators are now targeting AI traceability. This brief examines how leading regulatory teams are building AI governance frameworks — and what the unprepared are missing ahead of FDA inspections.
AI Readiness in Safety Compliance
LucidBio Intelligence
2025
Competitive Intelligence · 2025
Therapeutic Area Coverage
Deep therapeutic expertise means faster ramp-up, stronger regulatory arguments, and fewer surprises at FDA.
Why LucidBio
Case Studies
Drawn from our team's direct program experience across therapeutic areas, company sizes, and submission types. All examples are composite representations.
Coordinated a complex global regulatory submission spanning FDA, EMA, Swiss Medic, and Japan — synchronized briefing document development and multi-agency engagement strategy under a Breakthrough Therapy timeline.
All regulatory milestones achieved. Multi-agency submissions filed successfully. Program advanced through regulatory review leveraging BTD benefits.
A mid-size biotech preparing an FDA submission for an AML therapy faced inconsistent internal interpretations of clinical and biomarker data across functions, creating risk to regulatory clarity and approval timelines. We established a single cross-functional evidence strategy and unified the regulatory narrative.
An early-stage ophthalmology biotech needed to raise its profile among retinal specialists and strengthen corporate positioning ahead of acquisition discussions. We designed a focused HCP and KOL engagement strategy and unified clinical, scientific, and corporate communications under a single framework.
Trial enrollment accelerated by 35%. Recruitment targets met three months early. Company positioned centrally in AstraZeneca acquisition discussions.
A lean startup with no in-house regulatory infrastructure needed comprehensive support from Orphan Drug Designation through BLA submission — CSR development, protocol management, IB authorship, briefing documents, and full publication management.
Orphan Drug Designation secured. BLA submitted successfully. All clinical documentation completed on timeline. Publication strategy executed.
A seed-stage European biotech developing a novel oncology asset faced a critical Phase II protocol challenge — including endpoint selection, population heterogeneity, and statistical plan alignment. A three-pillar refinement strategy aligned the protocol with CHMP-guided precedents and achieved Scientific Advice validation.
Streamlined Scientific Advice validated the strategy. Proposed Phase II trial confirmed feasible. 6-month delay avoided. Company runway and timeline preserved.
An early-stage startup entering radiopharmaceuticals needed to build a regulatory program from scratch — no prior FDA experience, no in-house team, novel mechanism. We built the regulatory infrastructure, authored the Phase 1 IND package, and established the FDA engagement strategy.
Phase 1 IND submitted and cleared by FDA. First-in-human study initiated on schedule. Regulatory foundation established for ongoing program development.
A mid-size pharmaceutical company received a CRL from FDA for their pulmonology NDA — requiring immediate strategic response, full briefing document redevelopment, and AdComm and PDAC preparation under significant timeline pressure.
Successful NDA resubmission following CRL resolution. AdComm and PDAC proceedings navigated successfully. Program advanced to approval milestone.
A mid-size biotech 18 months from BLA submission managed five simultaneous submission-critical workstreams: multi-partner commercial alignment, CMC & manufacturing site validation, BIMO inspection readiness, companion diagnostic regulatory sync, and new alliance data integration.
Program on track. BLA moved forward. Full visibility restored across all five workstreams. Inspection-ready before it needed to be.
"LucidBio helped us see more clearly as a team. The approval felt inevitable by the time we submitted."
Complimentary Starting Point
An honest, expert gap analysis of where your program stands against what FDA will expect at your next major milestone. No obligation. No pitch deck. Just a candid conversation between people who have been in this room before.
Review of your lead program against current FDA expectations for your modality and indication.
The regulatory gaps most likely to create friction at your next milestone — surfaced before they cost you time.
How comparable programs have fared with FDA in your indication — what worked, what didn't.
A direct conversation with a LucidBio expert who has personally led a comparable program through FDA.
Start with a complimentary FDA Readiness Review — no obligation, no pitch deck. Just honest expert guidance.
Whether you're preparing an IND, navigating a CRL, building competitive intelligence ahead of a financing round, or need AI safety compliance guidance — we respond within one business day.
United States · Netherlands · United Kingdom
hello [at] lucidbiointelligence.com
We respond within 1 business day. All inquiries treated as confidential.
✓ Message received — we will be in touch within one business day.
Frequently Asked Questions